Titre : | Examining the limits of the buprenorphine interdosing interval: daily, every-third-day and every-fifth-day dosing regimens |
Titre traduit : | (Etude des limites d'efficacité de la buprénorphine selon les intervalles entre les doses administrées : posologie journalière, tous les trois jours et tous les cinq jours.) |
Auteurs : | N. M. PETRY ; W. K. BICKEL ; G. J. BADGER |
Type de document : | Périodique |
Année de publication : | 2001 |
Format : | 823-834 / graph. ; tabl. |
Note générale : |
Addiction, 2001, 96, (6), 823-834 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BUPRENORPHINE ; POSOLOGIE ; EFFICACITE ; DOSE-REPONSE ; SYNDROME DE SEVRAGE |
Résumé : |
FRANÇAIS : L'évaluation des symptômes de sevrage, à 24 h, 72 h. et 120 h., chez 33 sujets dépendants des opioïdes recevant soit une dose de base journalière de buprénorphine (4 ou 8 mg/kg), soit une dose triplée ou quintuplée, et ceci de façon aléatoire ou selon leur choix, montre que la durée maximum d'action de la buprénorphine est inférieure à 5 jours quand la dose administrée correspond à 5 fois la dose journalière de base. ENGLISH : Aims. Opioid-dependent outpatients may be more likely to present for pharmacological treatment if less than daily dosing can be arranged. These studies compared opioid withdrawal symptoms during 24-, 72-, and 120-hour buprenorphine dosing regimens and evaluated participants' preferences for these different dosing regimens. Participants. Thirty-three opioid-dependent participants received daily sublingual maintenance doses of 4 mg/7O kg (n=14) or 8 mg/70 kg (n=19) of liquid buprenorphine. Methods. In Study I participants received, in a random order, three dosing regimens for five repetitions of each: daily maintenance doses every 24 hours (4 or 8 mg/70 kg), triple the daily maintenance dose every 72 hours (12 or 24 mg/70 kg) and quintuple the daily maintenance dose every 120 hours (20 or 40 mg/70 kg). Doses were administered under double-blind procedures, and placebos were administered on the interposed days during the latter two regimens. Subjective and observer ratings of opioid withdrawal symptoms were assessed daily prior to receipt of each dose. In Study II, a new group of participants received each of the three dosing regimens under open-dosing procedures and then chose between the different dosing regimens. Findings. Opioid withdrawal symptoms increased significantly during the every-fifth-day dosing regimen in both the blind- and open-dosing studies. In the choice phase of Study II, only one participant (7%) chose quintuple-every-fifth-day dosing over all other dosing options. Conclusions. These results suggest that the maximum duration of action of buprenorphine is less than 5 days when five times the daily maintenance dose is provided. (Author' s abstract) |
Note de contenu : | graph. ; tabl. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 22 |
Affiliation : |
Univ. Vermont, Dprt Psychiatry, Psychology and Medical Biostatistics, Substance Abuse Treatment Center, 1 South Prospect Street, Burlington, VT. Etats-Unis. United States. |
Numéro Toxibase : | 205645 |
Centre Emetteur : | 02 Coordonnateur |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil